Literature DB >> 24276018

Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells.

Mercedes Martín-Rufián1, Renata Nascimento-Gomes, Ana Higuero, Amanda R Crisma, José A Campos-Sandoval, María C Gómez-García, Carolina Cardona, Tzuling Cheng, Carolina Lobo, Juan A Segura, Francisco J Alonso, Monika Szeliga, Jan Albrecht, Rui Curi, Javier Márquez, Alison Colquhoun, Ralph J Deberardinis, José M Matés.   

Abstract

UNLABELLED: Mitochondrial glutaminase (GA) plays an essential role in cancer cell metabolism, contributing to biosynthesis, bioenergetics, and redox balance. Humans contain several GA isozymes encoded by the GLS and GLS2 genes, but the specific roles of each in cancer metabolism are still unclear. In this study, glioma SFxL and LN229 cells with silenced isoenzyme glutaminase KGA (encoded by GLS) showed lower survival ratios and a reduced GSH-dependent antioxidant capacity. These GLS-silenced cells also demonstrated induction of apoptosis indicated by enhanced annexin V binding capacity and caspase 3 activity. GLS silencing was associated with decreased mitochondrial membrane potential (ΔΨm) (JC-1 dye test), indicating that apoptosis was mediated by mitochondrial dysfunction. Similar observations were made in T98 glioma cells overexpressing glutaminase isoenzyme GAB, encoded by GLS2, though some characteristics (GSH/GSSG ratio) were different in the differently treated cell lines. Thus, control of GA isoenzyme expression may prove to be a key tool to alter both metabolic and oxidative stress in cancer therapy. Interestingly, reactive oxygen species (ROS) generation by treatment with oxidizing agents: arsenic trioxide or hydrogen peroxide, synergizes with either KGA silencing or GAB overexpression to suppress malignant properties of glioma cells, including the reduction of cellular motility. Of note, negative modulation of GLS isoforms or GAB overexpression evoked lower c-myc and bcl-2 expression, as well as higher pro-apoptotic bid expression. Combination of modulation of GA expression and treatment with oxidizing agents may become a therapeutic strategy for intractable cancers and provides a multi-angle evaluation system for anti-glioma pre-clinical investigations. KEY MESSAGE: Silencing GLS or overexpressing GLS2 induces growth inhibition in glioma cell lines. Inhibition is synergistically enhanced after arsenic trioxide (ATO) or H2O2 treatment. Glutatione levels decrease in GLS-silenced cells but augment if GLS2 is overexpressed. ROS synergistically inhibit cell migration by GLS silencing or GLS2 overexpression. c-myc, bid, and bcl-2 mediate apoptosis resulting from GLS silencing or GLS2 overexpression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24276018      PMCID: PMC4327995          DOI: 10.1007/s00109-013-1105-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  39 in total

Review 1.  A novel glutaminase isoform in mammalian tissues.

Authors:  Vanessa de la Rosa; José A Campos-Sandoval; Mercedes Martín-Rufián; Carolina Cardona; José M Matés; Juan A Segura; Francisco J Alonso; Javier Márquez
Journal:  Neurochem Int       Date:  2009-03-09       Impact factor: 3.921

Review 2.  New insights into brain glutaminases: beyond their role on glutamatergic transmission.

Authors:  Javier Márquez; Marta Tosina; Vanessa de la Rosa; Juan A Segura; Francisco J Alonso; José M Matés; José A Campos-Sandoval
Journal:  Neurochem Int       Date:  2009-03-09       Impact factor: 3.921

3.  Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species.

Authors:  Sawako Suzuki; Tomoaki Tanaka; Masha V Poyurovsky; Hidekazu Nagano; Takafumi Mayama; Shuichi Ohkubo; Maria Lokshin; Hiroyuki Hosokawa; Toshinori Nakayama; Yutaka Suzuki; Sumio Sugano; Eiichi Sato; Toshitaka Nagao; Koutaro Yokote; Ichiro Tatsuno; Carol Prives
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

4.  Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.

Authors:  Wenwei Hu; Cen Zhang; Rui Wu; Yvonne Sun; Arnold Levine; Zhaohui Feng
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-08       Impact factor: 11.205

5.  c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.

Authors:  Ping Gao; Irina Tchernyshyov; Tsung-Cheng Chang; Yun-Sil Lee; Kayoko Kita; Takafumi Ochi; Karen I Zeller; Angelo M De Marzo; Jennifer E Van Eyk; Joshua T Mendell; Chi V Dang
Journal:  Nature       Date:  2009-02-15       Impact factor: 49.962

Review 6.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation.

Authors:  Ralph J DeBerardinis; Julian J Lum; Georgia Hatzivassiliou; Craig B Thompson
Journal:  Cell Metab       Date:  2008-01       Impact factor: 27.287

7.  Antisense glutaminase inhibition modifies the O-GlcNAc pattern and flux through the hexosamine pathway in breast cancer cells.

Authors:  Ana C Donadio; Carolina Lobo; Marta Tosina; Vanessa de la Rosa; Mercedes Martín-Rufián; José A Campos-Sandoval; José M Matés; Javier Márquez; Francisco J Alonso; Juan A Segura
Journal:  J Cell Biochem       Date:  2008-02-15       Impact factor: 4.429

8.  Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells.

Authors:  Monika Szeliga; Marta Obara-Michlewska; Ewa Matyja; Marzena Łazarczyk; Carolina Lobo; Wojciech Hilgier; Francisco J Alonso; Javier Márquez; Jan Albrecht
Journal:  Glia       Date:  2009-07       Impact factor: 7.452

9.  MYC, microRNAs and glutamine addiction in cancers.

Authors:  Chi V Dang
Journal:  Cell Cycle       Date:  2009-10-15       Impact factor: 4.534

Review 10.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

View more
  28 in total

1.  A comparative pharmaco-metabolomic study of glutaminase inhibitors in glioma stem-like cells confirms biological effectiveness but reveals differences in target-specificity.

Authors:  Jaroslaw Maciaczyk; Ulf D Kahlert; Katharina Koch; Rudolf Hartmann; Julia Tsiampali; Constanze Uhlmann; Ann-Christin Nickel; Xiaoling He; Marcel A Kamp; Michael Sabel; Roger A Barker; Hans-Jakob Steiger; Daniel Hänggi; Dieter Willbold
Journal:  Cell Death Discov       Date:  2020-04-16

Review 2.  Targeting metabolism in breast cancer: How far we can go?

Authors:  Jing-Pei Long; Xiao-Na Li; Feng Zhang
Journal:  World J Clin Oncol       Date:  2016-02-10

3.  Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer.

Authors:  Lingqin Yuan; Xiugui Sheng; Leslie H Clark; Lu Zhang; Hui Guo; Hannah M Jones; Adam K Willson; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 4.  A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.

Authors:  William P Katt; Michael J Lukey; Richard A Cerione
Journal:  Future Med Chem       Date:  2017-01-23       Impact factor: 3.808

Review 5.  Targeting mitochondria metabolism for cancer therapy.

Authors:  Samuel E Weinberg; Navdeep S Chandel
Journal:  Nat Chem Biol       Date:  2015-01       Impact factor: 15.040

6.  Silencing of miR-23a attenuates hydrogen peroxide (H2O2) induced oxidative damages in ARPE-19 cells by upregulating GLS1: an in vitro study.

Authors:  Yang Zhou; Meilibanu Yusufu; Ting Zhang; Jing Wang
Journal:  Cytotechnology       Date:  2020-10-29       Impact factor: 2.058

Review 7.  Glutaminolysis as a target for cancer therapy.

Authors:  L Jin; G N Alesi; S Kang
Journal:  Oncogene       Date:  2015-11-23       Impact factor: 9.867

Review 8.  Glutamine Addiction In Gliomas.

Authors:  Javier Márquez; Francisco J Alonso; José M Matés; Juan A Segura; Mercedes Martín-Rufián; José A Campos-Sandoval
Journal:  Neurochem Res       Date:  2017-03-09       Impact factor: 3.996

9.  Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma.

Authors:  Decai Yu; Xianbiao Shi; Gang Meng; Jun Chen; Chen Yan; Yong Jiang; Jiwu Wei; Yitao Ding
Journal:  Oncotarget       Date:  2015-04-10

10.  METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.

Authors:  Xiaoting Chen; Lanlan Huang; Tingting Yang; Jiexuan Xu; Chengyong Zhang; Zhendong Deng; Xiaorong Yang; Naihua Liu; Size Chen; Shaoqiang Lin
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.